Abstract Purpose Objectives: Cell cycle progression and DNA synthesis are essential steps in cancer cell growth and resistance. Thymidylate synthase (TS) is a therapeutic target for 5FU. Curcumin is a potent inhibitor of NF-κB. We tested the hypothesis that NF-κB translocation inhibition by curcumin and its analogs can inhibit cell cycle progression and downregulate TS levels in colorectal cell lines. Methods: Two colorectal cancer cell lines were usedHCT-116 and HT-29. Cells were either untreated (control) or treated with curcumin (20μM), EF31 (7.5μM for HCT-116 and 2.5μM for HT-29) and UBS109 (620nM for HCT-116 and 1.25μM for HT-29) for 24 hours. Western blot and RT-PCR analyses were carried out to determine the effect of curcumin and its analogues EF31 and UBS109 on different signal molecules involved in cell cycle arrest and DNA synthesis. Electromobility shift assay (EMSA) was performed in colon cancer cells to evaluate the effects of curcumin and its analogues on NF-κB activity. A subcutaneous xenograft mouse model was used to evaluate the in vivo effects of curcumin analogues. Results: Treatment with curcumin and its analogues inhibited cyclin D1, pRb and E2F-1 at the transcriptional and translational level and induced p21, leading to G0/G1 cell cycle arrest. NF-κB over-expression induced E2F-1 and TS protein and mRNA levels in both cell lines. Arrest in the G0/G1 phase was associated with downregulation of the transcription factor E2F-1 and its target gene TS. Similar effects were observed in tumors from animals treated with EF31 and UBS109. Further, EF31 and UBS109 treatment significantly decreased the tumor growth compared to untreated tumors. Conclusion: In this study, we present in vitro and in vivo data to support the use of curcumin analogs in colorectal cancer based on their ability to reduce expression of proteins important for DNA repair and cell cycle progression leading to cell cycle arrest and tumor shrinkage. Accordingly, combining curcumin analogs with chemotherapy is a rational approach for future drug development in colorectal cancer. Citation Format: Ganji Purnachandra Nagaraju, Alese Olatunji, Sandhya Gupta, Mamoru Shoji, Bassel F. El-Rayes. Inhibition of NF-κB translocation induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3778. doi:10.1158/1538-7445.AM2015-3778
Read full abstract